Biomarker assays for personalised stroke risk assessment in atrial fibrillation.

Biomarker assays for personalised stroke risk assessment in atrial fibrillation.
Cardiovasc Hematol Disord Drug Targets. 2017 Jan 04;
Authors: Hall A, Simpson RF, Mitchell AR
Abstract
Atrial fibrillation is a well-known independent risk factor for stroke yet there is no international consensus on guidelines regarding the introduction of anticoagulation in patients deemed at intermediate risk (e.g. CHA₂DS₂-VASc of 1). The evolution of cardiac biomarkers such as highly sensitive troponins and B-type natriuretic peptide as well as data on D-dimers, may offer incremental enhancements for personalised thromboembolism risk assessment. These markers provide prognostic data for risk of cardiovascular morbidities associated with atrial fibrillation and offer additional specificity for assessing stroke and thromboembolic risk. These assays may therefore enhance risk prognosis in atrial fibrillation alongside conventional stroke risk stratification tool patients. We seek to explore the application of personalised risk assessment using the biomarkers to aid the clinician treating the patient with atrial fibrillation deemed to be at intermediate risk of stroke.
PMID: 28056733 [PubMed - as supplied by publisher]

Source: Cardiovascular and Hematological Disorders Drug Targets - January 7, 2017 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research